Treatment of head and neck cancers:Issues for clinical pharmacists

Pharmacotherapy

Volumn 29, Issue 5, 2009, Pages 578-592

  Scarpace, Sarah L ^a   Brodzik, Frank A ^b   Mehdi, Syed ^b   Belgam, Robert ^b  

^a ALBANY COLLEGE OF PHARMACY AND HEALTH SCIENCES   (United States)

^b STRATTON VA MEDICAL CENTER   (United States)

Author keywords

Amifostine; Aprepitant; Cancer supportive care; Chemoradiation, cetuximab; Cisplatin; Docetaxel; Head and neck cancer; Oncology; Ppharmacy practice

Indexed keywords

AMIFOSTINE; APREPITANT; CARBOPLATIN; CETUXIMAB; CISPLATIN; DEXAMETHASONE; DOCETAXEL; ERYTHROPOIETIN; FLUOROURACIL; HYDROXYUREA; PACLITAXEL; PALIFERMIN; PALONOSETRON; PILOCARPINE;

ACNE; ADJUVANT THERAPY; ANEMIA; BONE MARROW SUPPRESSION; CANCER CHEMOTHERAPY; CANCER PATIENT; CANCER RADIOTHERAPY; CANCER STAGING; CLINICAL TRIAL; CONTINUOUS INFUSION; DRUG CLEARANCE; DRUG EFFICACY; DRUG FATALITY; DRUG MEGADOSE; DYSPHAGIA; FEBRILE NEUTROPENIA; HEAD AND NECK CANCER; HUMAN; HYPOMAGNESEMIA; LEUKOPENIA; LOW DRUG DOSE; METASTASIS; MOUTH HYGIENE; MOUTH PAIN; MUCOSA INFLAMMATION; MULTIMODALITY CANCER THERAPY; MULTIPLE CYCLE TREATMENT; NAUSEA AND VOMITING; NEUTROPENIA; PHARMACIST; RADIATION DERMATITIS; RASH; REVIEW; SCIENTIFIC LITERATURE; SIDE EFFECT; SINGLE DRUG DOSE; SKIN TOXICITY; STOMATITIS; UNSPECIFIED SIDE EFFECT; WEIGHT REDUCTION; XEROSTOMIA;

ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; CARBOPLATIN; CISPLATIN; COMBINED MODALITY THERAPY; DERMATITIS; HEAD AND NECK NEOPLASMS; HUMANS; MEDICATION THERAPY MANAGEMENT; MUCOSITIS; PHARMACEUTICAL SERVICES; RADIOTHERAPY; SURVIVAL ANALYSIS; XEROSTOMIA;

EID: 66249123936     PISSN: 02770008     EISSN: None     Source Type: Journal    
DOI: 10.1592/phco.29.5.578     Document Type: Review

References (81)

1. Ries LAG, Melbert D, Krapcho M, et al, eds. Surveillance epidemiology and end results. SEER cancer statistics review, 1975-2004. Bethesda, MD: National Cancer Institute, 2007.Available from http://seer.cancer.gov/csr/1975-2004/. Accessed July 31, 2007.
2. American Cancer Society. Cancer facts and figures 2007. Atlanta, GA; 2007. Available from www.cancer.org/downloads/STT/caff2007PWSecured.pdf. Accessed July 31, 2007.
3. D'Souza G, Kreimer AR, Viscidi R, et al. Case-control study of human papillomavirus and oropharyngeal cancer. N Engl J Med 2007;356:1944-56.
4. Worden FP, Kumar B, Lee JS, et al. Chemoselection as a strategy for organ preservation in oropharynx cancer: response and survival positively associated with HPV16 copy number. J Clin Oncol 2008;26(19):3138-46.
5. Kumar B, Cordell KG, Lee JS, et al. EGFR, p16, HPV titer, BclxL and p53, sex, and smoking as indicators of response to therapy and survival in oropharyngeal cancer. J Clin Oncol 2008;26(19):3128-37.
6. Singh B, Pfister DG. Individualized treatment selection in patients with head and neck cancer: do molecular markers meet the challenge? J Clin Oncol 2008;26(19):3114-16.
7. U.S. National Institutes of Health. ClinicalTrials.gov. Available from http://clinicaltrials.gov/. Accessed May 30, 2008.
8. Nemunaitis JJ. A phase 3, multi-center, open-label randomized study of adenoviral p53 gene therapy (Advexin®) versus methotrexate in patients with recurrent, refractory squamous cell carcinoma of the head and neck (SCCHN). Presented at the 11th annual meeting of the American Society for Gene Therapy, Boston, MA, May 29-June 1, 2008. Available from http://library.corporate-ir.net/ library/12/121/121960/items/295964/2008ASGTPresentationFINAL.pdf.
9. National Comprehensive Cancer Network. Clinical practice guidelines in oncology: head and neck cancer v.1.2007. Available from www.nccn.org. Accessed May 30, 2008.
10. Horiot JC, Le Fur R, N'Guyen T, et al. Hyperfractionation versus conventional fractionation in oropharyngeal carcinoma: final analysis of a randomized trial of the EORTC cooperative group of radiotherapy. Radiother Oncol 1992;25:231-41.
11. Fu KK, Pajak TF, Trotti A, et al. A radiation therapy oncology group (RTOG) phase III randomized study to compare hyperfractionation and two variants of accelerated fractionation to standard fractionation radiotherapy for head and neck squamous cell carcinoma: first report of RTOG 90-03. Int J Radiation Oncol Biol Phys 2000;48:7-16.
12. Horiot JC, Bontemps P, Lagarde C. Accelerated fractionation (AF) compared to conventional fractionation (CF) improves locoregional control in the radiotherapy of advanced head and neck cancers: results of EORTC 22851 trial. Radiother Oncol 1997;44:111-21.
13. Department of Veterans Affairs Laryngeal Cancer Study Group. Induction chemotherapy plus radiation compared with surgery plus radiation in patients with advanced laryngeal cancer. N Engl J Med 1991;324:1685-90.
14. Hong WK, Lippman SM, Wolf GT. Recent advances in head and neck cancer: larynx preservation and cancer chemoprevention the seventeenth annual Richard and Hinda Rosenthal foundation award lecture. Cancer Res 1993;53:5113-20.
15. Forastiere AA, Goepfert H, Maor M, et al. Concurrent chemotherapy and radiotherapy for organ preservation in advanced laryngeal cancer. N Engl J Med 2003;349:2091-8.
16. Adelstein DJ, Li Y, Adams GL, et al. An intergroup phase III comparison of standard radiation and two schedules of concurrent chemoradiotherapy in patients with unresectable squamous cell head and neck cancer. J Clin Oncol 2003;21:92-8.
17. Boscolo-Rizzo P, Maronato F, Marchiori C, Gava A, DaMosto MC. Long-term quality of life after total laryngectomy and postoperative radiotherapy versus concurrent chemoradiotherapy for laryngeal preservation. Laryngoscope 2008;118:300-6.
18. Mowry SE, Ho A, Lotempio MM, Sadeghi A, Blackwell KE, Wang MB. Quality of life in advanced oropharyngeal carcinoma after chemoradiation versus surgery and radiation. Laryngoscope 2006;116:1589-93.
19. Machtay M, Moughan J, Trotti A, et al. Factors associated with severe late toxicity after concurrent chemoradiation for locally advanced head and neck cancer: an RTOG analysis. J Clin Oncol 2008;26(21):3582-9.
20. Bachaud JM, Cohen-Jonathan E, Alzieu C, et al. Combined post-operative radiotherapy and weekly cisplatin infusion for locally advanced head and neck carcinoma: final report of a randomized trial. Int J Radiat Oncol Biol Phys 1996;36:999-1004.
21. Al-Sarraf M, LeBlanc M, Giri PG, et al. Chemoradiotherapy versus radiotherapy in patients with advanced nasopharyngeal cancer: phase III randomized intergroup study 0099. J Clin Oncol 1998;16:1310-17.
22. Garden AS, Harris J, Vokes EE, et al. Preliminary results of radiation therapy oncology group 97-03: a randomized phase II trial of concurrent radiation and chemotherapy for advanced squamous cell carcinomas of the head and neck. J Clin Oncol 2004;22:2856-64.
23. Bonner JA, Harari PM, Giralt J, et al. Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck. N Engl J Med 2006;354:567-78.
24. National Comprehensive Cancer Network. Clinical practice guidelines in oncology: antiemesis v.3.2008. Available from www.nccn.org. Accessed October 18, 2008.
25. DiPiro CV. Nausea and vomiting. In: DiPiro JT, Talbert RL, Yee GC, Matske GR, Wells BG, Posey LM, eds. Pharmacotherapy: a pathophysiologic approach, 7th ed. New York, NY: McGraw Hill Medical, 2008:607-16.
26. Jacobs C, Lyman G, Velez-Garcia E, et al. A phase III randomized study comparing cisplatin and fluorouracil as single agents and in combination for advanced squamous cell carcinoma of the head and neck. J Clin Oncol 1992;10:257-63.
27. Chitaparinux I, Lorvidhayan V, Kamnerdsupaphon P, et al. Chemoradiation comparing cisplatin versus carboplatin in locally advanced nasopharyngeal cancer: randomized, noninferiority, open trial. Eur J Cancer 2007;43:1399-406.
28. Bourhis J, Rivera F, Mesia R, et al. Phase I/II study of cetuximab in combination with cisplatin or carboplatin and fluorouracil in patients with recurrent or metastatic squamous cell carcinoma of the head and neck. J Clin Oncol 2006;24:2866-72.
29. Baselga J, Trigo JM, Bourhis J, et al. Phase II multicenter study of the antiepidermal growth factor receptor monoclonal antibody cetuximab in combination with platinum-based chemotherapy in patients with platinum-refractory metastatic and/or recurrent squamous cell carcinoma of the head and neck. J Clin Oncol 2005;24:5568-77.
30. Adelstein DJ, LeBlanc M. Does induction chemotherapy have a role in the management of locoregionally advanced squamous cell head and neck cancer? J Clin Oncol 2006;24:2624-8.
31. Adelstein DJ. Redefining the role of induction chemotherapy in head and neck cancer. J Clin Oncol 2008;26(19):3117-19.
32. Glynne-Jones R, Hoskin P. Neoadjuvant cisplatin before chemoradiation: a flawed paradigm? J Clin Oncol 2007;25:5281-6.
33. Specenier PM, Vermorken JB. Neoadjuvant chemotherapy for head and neck cancer: should it be revisited? Cancer Lett 2007;256:166-77.
34. Gibson MK, Forastiere AA. Reassessment of the role of induction chemotherapy for head and neck cancer. Lancet Oncol 2006;7:565-74.
35. Pfister DG, Ridge JA. Induction chemotherapy for larynx preservation: patient selection or therapeutic effect? J Clin Oncol 2006;24:540-3.
36. Posner MR. Paradigm shift in the treatment of head and neck cancer: the role of neoadjuvant chemotherapy. Oncologist 2005;10(suppl 3):11-19.
37. Adelstein DJ. Induction redux: once more with taxanes. J Clin Oncol 2005;23:8556-8.
38. Argiris A. Induction chemotherapy for head and neck cancer: will history repeat itself? J Natl Compr Canc Netw 2005;3:393-403.
39. Garden AS. Is there still a role for induction chemotherapy in head and neck cancer? J Clin Oncol 2005;23:1059-60.
40. Posner MR, Haddad RI, Wirth L, et al. Induction chemotherapy in locally advanced squamous cell cancer of the head and neck: evolution of the sequential treatment approach. Semin Oncol 2004;31:778-85.
41. Forastiere AA. Is there a new role for induction chemotherapy in the treatment of head and neck cancer? J Natl Cancer Inst 2004;96:1647-9.
42. Forastiere AA, Trotti A, Pfister DG, Grandis JR. Head and neck cancer: recent advances and new standards of care. J Clin Oncol 2006;24:2603-5.
43. Cmelak AJ, Li S, Goldwasser MA, et al. Phase II trial of chemoradiation for organ preservation in resectable stage III or IV squamous cell carcinomas of the larynx or oropharynx: results of the eastern cooperative oncology group study E2399. J Clin Oncol 2007;25:3971-7.
44. Urba SG, Moon J, Giri PG, et al. Organ preservation for advanced resectable cancer of the base of tongue and hypopharynx: a southwest oncology group trial. J Clin Oncol 2005;23:88-95.
45. Posner MR, Hershock DM, Blajman CR. Cisplatin and fluorouracil alone or with docetaxel for head and neck cancer. N Engl J Med 2007;357:1705-15.
46. Vermorken JB, Remenar E, van Herpen C, et al. Cisplatin, fluorouracil, and docetaxel in unresectable head and neck cancer. N Engl J Med 2007;357:1695-704.
47. Overgaard J, Hoff C, Sand Hansen H, et al. Randomized study of the importance of novel erythropoiesis stimulating protein (Aranesp) for the effect of radiotherapy in patients with primary squamous cell carcinoma of the head and neck (HNSCC): the Danish head and neck cancer group DAHANCA10 randomized trial [abstract]. Eur J Cancer Suppl 2007;5:7.
48. Henke M, Laszig R, Rube C, et al. Erythropoietin to treat head and neck cancer patients with anemia undergoing radiotherapy: randomised, double-blind, placebo-controlled trial. Lancet 2003;362:1255-60.
49. U.S. Food and Drug Administration, Center for Drug Evaluation and Research. Information on erythropoiesis stimulating agens (ESAs). Available from http://www.fda.gov/CDER/Drug/infopage/RHE/default.htm. Accessed February 27, 2009.
50. U.S. Food and Drug Administration, Center for Drug Evaluation and Research. Drugs@FDA, FDA approved drug products: Erbitux. Available from www.accessdata.fda.gov/scripts/cder/drugsatfda/index.cfm?fuseaction=Search. Label-ApprovalHistory#apphist. Accessed May 31, 2008.
51. Vermorken JB, Trigo J, Hitt R, et al. Open-label, uncontrolled, multicenter phase II study to evaluate the efficacy and toxicity of cetuximab as a single agent in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck who failed to respond to platinum-based therapy. J Clin Oncol 2007;25:2171-7.
52. Burtness B, Goldwasser MA, Flood W, Mattar B, Forastiere AA, for the Eastern Cooperative Oncology Group. Phase III randomized trial of cisplatin plus placebo compared to cisplatin plus cetuximab in metastatic/recurrent head and neck cancer:an eastern cooperative oncology group study. J Clin Oncol 2005;23:8646-54.
53. Pfister DG, Su YB, Kraus DH, et al. Concurrent cetuximab, cisplatin, and concomitant boost radiotherapy for locoregionally advanced, squamous cell head and neck cancer: a pilot phase II study of a new combined-modality paradigm. J Clin Oncol 2006;24(7):1072-8.
54. Posner MR, Wirth LJ. Cetuximab and radiotherapy for head and neck cancer. N Engl J Med 2006;354:634-6.
55. The Joint Commission on Accreditation of Healthcare Organizations. The Joint Commission accreditation program: 2008 hospital national patient safety goals, goal 8. Available from http://www.jointcommission.org/NR/rdonlyres/ 31666E86-E7F4-423E-9BE8-F05BD1CB0AA8/0/HAP-NPSG.pdf. Accessed February 27, 2009.
56. American Society of Health-System Pharmacists. ASHP medication reconciliation toolkit. Available from www.ashp. org/Import/PRACTICEANDPOLICY/ PracticeResourceCenters /PatientSafety/ASHPMedicationReconciliationToolkit-1. aspx. Accessed July 2, 2008.
57. Carnaby-Mann G, App Sci B, Dip PGrad, Crary M. Pill swallowing by adults with dysphagia. Arch Otolaryngol Head Neck Surg 2005;131:970-5.
58. Mitchell JF. Oral dosage forms that should not be crushed. Available from www.ismp.org/Tools/DoNotCrush.pdf. Accessed July 2, 2008.
59. Lasseter KC, Gambale J, Jin B, et al. Tolerability of fosaprepitant and bioequivalency to aprepitant in healthy subjects. J Clin Pharmacol 2007;47:834-40.
60. Herrington JD, Jaskiewicz AD, Song J. Randomized, placebocontrolled pilot study evaluating aprepitant single dose plus palonosetron and dexamethasone for the prevention of acute and delayed chemotherapy-induced nausea and vomiting. Cancer 2008;112:2080-7.
61. Dirix P, Nuyts S, Van den Bogaert W. Radiation-induced xerostomia in patients with head and neck cancer. Cancer 2006;107:2525-34.
62. Wasserman TH, Brizel DM, Henke M, et al. Influence of intravenous amifostine on xerostomia, tumor control, and survival after radiotherapy for head-and-neck cancer: 2-year follow-up of a prospective, randomized phase III trial. Int J Radiat Oncol Biol Phys 2005;63:985-90.
63. Hensley ML, Schuchter LM, Lindley C, et al. American Society of Clinical Oncology clinical practice guideline for the use of chemotherapy and radiotherapy protectants. J Clin Oncol 1999;17:3333-55.
64. Johnson JT, Ferretti G, Netery W, et al. Oral pilocarpine for post-irradiation xerostomia in patients with head and neck cancer. N Engl J Med 1993;329:390-5.
65. Scarantino C, LeVeque F, Swann RS. Effect of pilocarpine during radiation therapy: results of RTOG 97-09, a phase III randomized study in head and neck cancer patients. J Support Oncol 2006;4:252-8.
66. Burlage PF, Roesink JM, Kampinga HH, et al. Protection of salivary function by concomitant pilocarpine during radiation therapy: a double-blind, randomized, placebo-controlled study. Int J Radiat Oncol Biol Phys 2008;70:14-22.
67. Chamber MS, Posner M, Jones CO, et al. Cevimeline for the treatment of post-irradiation xerostomia in patients with head and neck cancer. Int J Radiat Oncol Biol Phys 2007;68:1102-9.
68. Peterson DE, Bensadoun RJ, Roila F. Management of oral and gastrointestinal mucositis: ESMO clinical recommendations. Ann Oncol 2008;19(suppl 2):ii122-5.
69. Bensadoun RJ, Schubert MM, Lalla RV, Keefe D. Amifostine in the management of radiation-induced and chemotherapyinduced mucositis. Support Care Cancer 2006;14:566-72.
70. Keefe DM, Schubert MM, Elting LS, et al. Updated clinical practice guidelines for the prevention and treatment of mucositis. Cancer 2007;109:820-31.
71. Carter DL, Hebert ME, Smith K, et al. Double blind randomized trial of sucralfate vs placebo during radical radiotherapy for head and neck cancers. Head Neck 1999;21:760-6.
72. Lievens Y, Haustermans K, Van der Weyngaert D, et al. Does sucralfate reduce the acute side effects in head and neck cancer treated with radiotherapy? A double-blind randomized trial. Radiother Oncol 1998;47:149-53.
73. Meredith R, Salter M, Kim R, et al. Sucralfate for radiation mucositis: results of a double-blind randomized trial. Int J Radiat Oncol Biol Phys 1997;37:275-9.
74. Makkonen TA, Bostrom P, Vilja P, et al. Sucralfate mouth washing in the prevention of radiation-induced mucositis: a placebo-controlled double-blind randomized study. Int J Radiat Oncol Biol Phys 1994;30:177-82.
75. Dodd MJ, Miaskowski C, Greenspan D, et al. Radiationinduced mucositis: a randomized clinical trial of micronized sucralfate versus salt and soda mouthrinses. Cancer Invest 2003;21:21-33.
76. Brizel DM, Murphy BA, Rosenthal DI, et al. Phase II study of palifermin and concurrent chemoradiation in head and neck squamous cell carcinoma. J Clin Oncol 2008;26:2489-96.
77. 2 laser. Int J Oral Maxillofac Surg 2006;35:514-17.
78. Barber C, Powell R, Ellis A, Hewett J. Comparing pain control and ability to eat and drink with standard therapy vs. Gelclair: a preliminary, double centre, randomized controlled trial on patients with radiotherapy-induced oral mucositis. Support Care Cancer 2007;15:427-40.
79. Motallebnejad M, Akram S, Moghadamnia A, Moulana Z, Omidi S. The effect of topical application of pure honey on radiation-induced mucositis: a randomized clinical trial. J Contemp Dent Pract 2008;9:40-7.
80. Biswal BM, Zakaria A, Ahmad NM. Topical application of honey in the management of radiation mucositis: a preliminary study. Support Care Cancer 2003;11:242-8.
81. Bernier J, Bonner J, Vermorken JB, et al. Consensus guidelines for the management of radiation dermatitis and coexisting acne-like rash in patients receiving radiotherapy plus EGFR inhibitors for the treatment of squamous cell carcinoma of the head and neck. Ann Oncol 2008;19:142-9.